Medihoney HCS, which comprises the company’s Medihoney and Xtrasorb HCS dressings, to treat first and second-degree burns, modulates MMPs protease enzymes and hydrates dry wounds and absorbs fluid from wounds that are draining.

Derma Sciences CEO Ed Quilty said Medihoney HCS will provide physicians and caretakers with an additional new wound dressing to help optimize their clinical outcomes.

"We plan to take this product to our domestic OTC customers and look forward to launching MEDIHONEY HCS in Europe early next year," Quilty added.

The company said it is planning to demonstrate Medihoney HCS, being held in Baltimore, Maryland, US, at the Symposium on Advanced Wound Care meeting.